Skip to main content

Table 3 Univariate analysis of prognostic factors

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Prognostic factor n Median OS (months) p value
Sex
 Male 75 6.5 0.052
 Female 29 10.6  
ECOG PS
 0 93 7.3 0.038
 1, 2 11 5.2  
Age
  ≥ 70 12 7 0.334
  < 70 92 7.3  
Pancreatic resection
 Yes 31 7 0.319
 No 73 8  
First-line therapy duration
  ≤ 4 months 19 7 0.459
  > 4 months 85 7.3  
Liver metastasis
 Yes 72 6.5 0.054
 No 32 9.9  
CEA (ng/mL)
  ≤ 10 69 9.9 < 0.001
  > 10 35 6.2  
CA19–9 (IU/mL)
  ≤ 1000 57 7.5 0.621
  > 1000 47 7  
Alb (g/dL)
  < 3.5 40 6 0.014
  ≥ 3.5 64 9.4  
CRP (mg/dL)
  ≤ 0.16 35 11.6 < 0.001
  > 0.16 69 5.9  
GPS
 Low (0) 44 10.6 < 0.001
 High (1, 2) 60 6  
NLR
  ≤ 5.0 96 8.7 < 0.001
  > 5.0 8 4.6  
  1. Alb albumin, CA19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, GPS Glasgow prognostic score, NLR neutrophil-to-lymphocyte ratio